METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Clinical trials for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HORMONE-SENSITIVE PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough prostate cancers: adding chemo to targeted therapy
Disease control Recruiting nowThis Phase 3 trial tests whether adding the chemotherapy drug docetaxel to the standard treatment (apalutamide plus hormone therapy) can help men with metastatic hormone-sensitive prostate cancer who did not have a strong initial response to apalutamide alone. About 320 men will …
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to slow prostate cancer spread
Disease control Recruiting nowThis study tests a new drug, JSB462, combined with standard therapy (abiraterone) in 150 men whose prostate cancer has spread but still responds to hormone treatment. The goal is to see if the combination lowers PSA levels more effectively and delays cancer growth. Participants w…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for advanced prostate cancer? early trial tests targeted combo therapy
Disease control Recruiting nowThis early-phase study is testing a new drug called pasritamig (JNJ-78278343) combined with other treatments for men with metastatic prostate cancer that no longer responds to hormone therapy. The goal is to find the safest and most effective dose. About 300 participants will be …
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New shot could simplify prostate cancer treatment
Disease control Recruiting nowThis phase 2 trial tests ASP5541, a new injectable form of the hormone therapy abiraterone, in men with advanced prostate cancer that has spread. The study compares ASP5541 (given every 12 weeks) to daily abiraterone pills, both with or without steroids. About 218 men with metast…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New radiation therapy shows promise for Tough-to-Treat prostate cancer
Disease control Recruiting nowThis study is testing a new treatment called [212Pb]Pb-ADVC001 for men with prostate cancer that has spread to other parts of the body. The treatment delivers a small amount of radiation directly to cancer cells. The study has two parts: first, finding the safest and most effecti…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: AdvanCell Pty Limited • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New prostate cancer drug tested in chinese men – early safety check
Disease control Recruiting nowThis early-phase study tests a new drug called ASP5541 in Chinese men with advanced prostate cancer. The drug is given as a shot in the hip, along with standard treatments prednisone and hormone therapy. The main goals are to check the drug's safety and how it is processed by the…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Could taking a break from hormone therapy be just as good for prostate cancer?
Disease control Recruiting nowThis study is for men with metastatic hormone-sensitive prostate cancer who have already been on hormone therapy for 6-12 months and have very low PSA levels. It compares two approaches: stopping and restarting treatment based on PSA levels (intermittent) versus staying on treatm…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Jun 26, 2026 19:20 UTC
-
Exercise study aims to boost quality of life for men with metastatic prostate cancer
Symptom relief Recruiting nowThis study tests whether a low to moderate load power training program can improve quality of life, strength, and balance in men with metastatic prostate cancer who are on hormone therapy. About 66 participants will either join a supervised exercise program twice a week for 6 mon…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: NA • Sponsor: University of Alicante • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Which prostate cancer drug is safer for the heart? new study aims to find out
Knowledge-focused Recruiting nowThis study looks at heart-related side effects in older men with advanced prostate cancer treated with enzalutamide or darolutamide. Researchers will analyze existing health records from 3,000 men aged 55 and older to compare rates of heart attacks, strokes, and heart-related dea…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Prostate cancer drug darolutamide under safety watch in korea
Knowledge-focused Recruiting nowThis study monitors the safety and effectiveness of darolutamide (Nubeqa) in 600 Korean men with non-metastatic or metastatic hormone-sensitive prostate cancer. Participants receive the drug as part of their normal care and are followed for one year. Researchers track side effect…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Russian prostate cancer study tracks real-world treatments and genetic clues
Knowledge-focused Recruiting nowThis study observes 400 men in Russia with aggressive, high-volume metastatic hormone-sensitive prostate cancer. Researchers will track which treatments doctors use (like hormone therapy, chemotherapy, or radiation) and test blood samples for genetic mutations. The goal is to und…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Prostate cancer Pill-Taking habits under the microscope
Knowledge-focused Recruiting nowThis study tracks 270 men with metastatic hormone-sensitive prostate cancer to see how faithfully they take their apalutamide pills over the first year. Researchers will use questionnaires to measure adherence and identify who is at risk of skipping doses. The goal is to learn wh…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Sponsor: Janssen Cilag S.A.S. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Massive global registry launches to track prostate cancer care worldwide
Knowledge-focused Recruiting nowThis study is a large international registry that will follow at least 5,000 men with advanced prostate cancer for five years or more. Researchers will collect detailed information on treatments, side effects, and quality of life to see which approaches work best. The goal is to …
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Sponsor: Prostate Cancer Clinical Trials Consortium • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Real-World study tracks darolutamide use in advanced prostate cancer
Knowledge-focused Recruiting nowThis study is not testing a new drug but rather observing how darolutamide is actually used in everyday urology clinics for men with metastatic hormone-sensitive prostate cancer. Researchers will review medical records of about 1,400 patients to understand who gets which treatmen…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC